Express Scripts Holding Company (ESRX) is a Fortune 100 pharmacy benefit manager (PBM) in the United States. It is the largest PBM in the nation and one of the largest in the world, with a network of more than 1 million pharmacies. The company processes prescriptions for members of health insurance plans, as well as managing mail-order pharmacies, specialty pharmacy services, and pharmacy benefit management services. It is also a major provider of prescription drug trend analysis data and related services.
History of Express Scripts
Express Scripts was founded in 1986 in St. Louis, Missouri. The company was originally called Medco Health Solutions and was co-founded by Steven and Edward Miller. The company was created to provide prescription services for employer-funded health plans. In 1992, the company went public and in 1994, it acquired a publicly traded competitor, Script-Med.
In 1998, the company merged with Merck-Medco Managed Care, a subsidiary of Merck, to become the largest PBM in the nation. In 2002, the company changed its name to Express Scripts and began expanding its services to include Medicare Part D and specialty pharmacy services. In 2009, Express Scripts acquired WellPoint’s NextRx business, making it the largest PBM in the nation.
Express Scripts Stock Price History
Express Scripts has a long history of success and its stock price reflects this. The stock has been publicly traded since 1992 and has seen steady growth. In 1998, the stock price was around $15 and by 2009, it had reached a high of $87. In 2010, the stock price reached a peak of $96 and has since settled in the $60 to $70 range.
The stock has been generally stable since 2010, with only a few short-term dips. The stock has benefited from the growth of the PBM industry as well as the increasing demand for prescription drug trend analysis data and related services. The stock also benefited from the company’s acquisition of WellPoint’s NextRx business in 2009.
What to Expect in the Future
Express Scripts is well-positioned to capitalize on the continued growth of the PBM industry. The company has a strong network of pharmacies and is a major provider of prescription drug trend analysis data and related services. The stock price should continue to be stable, with potential for growth in the future.
The company is also well-positioned to benefit from the increasing demand for specialty pharmacy services. Specialty pharmacy services are becoming increasingly important as the demand for specialty drugs grows. Express Scripts has the experience and expertise to provide these services, which should lead to increased demand for its services and a higher stock price.
Conclusion
Express Scripts has a long history of success and its stock price has been generally stable since 2010. The company is well-positioned to capitalize on the continued growth of the PBM industry and the increasing demand for specialty pharmacy services. The stock has potential for growth in the future and should remain a solid investment for investors.